Bronte Capital Management Pty Ltd. Regeneron Pharmaceuticals, Inc. Transaction History

Bronte Capital Management Pty Ltd.

$847 Million
Q3 2025

A detailed history of Bronte Capital Management Pty Ltd. transactions in Regeneron Pharmaceuticals, Inc. stock. As of the latest transaction made, Bronte Capital Management Pty Ltd. holds 180,283 shares of REGN stock, worth $125 Million. This represents 11.97% of its overall portfolio holdings.

Number of Shares

180,283

Previous 154,693 16.54%

Holding current value

$125 Million

Previous $98.1 Million 3.32%

% of portfolio

11.97%

Previous 10.4%

19 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Nov 04, 2025	BUY	$534.91 - $598.71 $13.7 Million - $15.3 Million	25,590 Added 16.54%	180,283 $101 Million
Q1 2025 May 13, 2025	BUY	$634.14 - $744.83 $1.21 Million - $1.42 Million	1,910 Added 1.25%	154,693 $98.1 Million
Q4 2024 Feb 10, 2025	BUY	$701.85 - $1046.91 $11 Million - $16.5 Million	15,741 Added 11.49%	152,783 $109 Million
Q3 2024 Nov 04, 2024	SELL	$1024.09 - $1201.76 $2.47 Million - $2.9 Million	-2,412 Reduced 1.73%	137,042 $144 Million
Q2 2024 Aug 07, 2024	SELL	$883.2 - $1071.19 $4.96 Million - $6.02 Million	-5,619 Reduced 3.87%	139,454 $147 Million

Q1 2024 May 13, 2024	SELL	$902.69 - $993.35 $314,136 - $345,685	-348 Reduced 0.24%	145,073 $140 Million
Q4 2023 Feb 07, 2024	BUY	$775.18 - $881.7 $3.08 Million - $3.51 Million	3,979 Added 2.81%	145,421 $128 Million
Q3 2023 Nov 06, 2023	BUY	$692.45 - $844.37 $2.16 Million - $2.64 Million	3,126 Added 2.26%	141,442 $116 Million
Q2 2023 Aug 07, 2023	BUY	$700.03 - $830.35 $1.36 Million - $1.61 Million	1,943 Added 1.42%	138,316 $99.4 Million
Q1 2023 May 12, 2023	SELL	$680.49 - $826.97 $4.32 Million - $5.25 Million	-6,350 Reduced 4.45%	136,373 $112 Million
Q4 2022 Feb 13, 2023	SELL	$705.89 - $766.39 $3.14 Million - $3.41 Million	-4,452 Reduced 3.02%	142,723 $103 Million
Q3 2022 Nov 02, 2022	SELL	$573.97 - $724.32 $1.16 Million - $1.46 Million	-2,014 Reduced 1.35%	147,175 $101 Million
Q2 2022 Aug 08, 2022	BUY	$548.35 - $738.84 $5.58 Million - $7.52 Million	10,172 Added 7.32%	149,189 $88.2 Million
Q1 2022 May 13, 2022	BUY	$595.12 - $698.43 $5.09 Million - $5.98 Million	8,557 Added 6.56%	139,017 $97.1 Million
Q4 2021 Feb 10, 2022	BUY	$543.48 - $670.97 $3.39 Million - $4.18 Million	6,236 Added 5.02%	130,460 $82.4 Million
Q3 2021 Nov 09, 2021	BUY	$574.03 - $680.96 $3.88 Million - $4.6 Million	6,755 Added 5.75%	124,224 $75.2 Million
Q2 2021 Aug 09, 2021	BUY	$472.8 - $558.54 $27.5 Million - $32.4 Million	58,082 Added 97.8%	117,469 $65.6 Million
Q1 2021 Apr 13, 2021	BUY	$446.73 - $548.2 $18 Million - $22.1 Million	40,334 Added 211.69%	59,387 $28.1 Million
Q4 2020 Feb 03, 2021	BUY	$478.3 - $607.98 $9.11 Million - $11.6 Million	19,053 New	19,053 $9.21 Million

Others Institutions Holding REGN

# of Institutions

1,467

Shares Held

86.5M

Call Options Held

2.42M

Put Options Held

1.64M

View Full List

About REGENERON PHARMACEUTICALS, INC.

Ticker REGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 107,190,000
Market Cap $74.3B
Description
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macula...

More about REGN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Bronte Capital Management Pty Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Bronte Capital Management Pty Ltd. with notifications on news.

Account

Bronte Capital Management Pty Ltd. Regeneron Pharmaceuticals, Inc. Transaction History